Review reveals that microbiota-mediated barrier dysfunction drives liver pathology in preclinical and clinical models, highlighting dietary and probiotic interventions.
Key Points
To summarize the mechanisms through which gut microbiota and their metabolites compromise intestinal barrier integrity to drive liver disease, while evaluating potential therapeutic strategies.
Synthesized findings from in vitro experiments, animal models, and human clinical investigations focusing on gut–liver axis pathophysiology.
Evaluated non-pharmacological interventions targeting gut dysbiosis and intestinal barrier function, specifically dietary modification, exercise, and probiotic supplementation.
Bacterial lipopolysaccharide stimulates Toll-like receptor signaling pathways associated with increased intestinal permeability and subsequent hepatic inflammation.
Lifestyle modifications, including increased physical activity and healthier diets, alongside probiotic administration, improve gut microbial composition and restore gut barrier integrity.